Female Reproduction

A newly diagnosed patient with three genuinely distinct problems — irregular cycles, biochemical insulin resistance, and hirsutism she treats as her real complaint — and three first-line drugs, each of which answers a different one of them best.

A patient whose insulin-resistant PCOS hasn't responded to six months of metformin asks for a GLP-1 agonist by name — a real, growing off-label pattern that a brand-new 2026 systematic review can now actually be measured against, rather than argued from enthusiasm alone.

A 28-year-old with primary ovarian insufficiency is offered the same menopausal HRT regimen her mother takes — a dosing target built for a 51-year-old's remaining biology, not hers.

A woman twelve years past menopause wants the hormone therapy her friend takes for hot flashes — testing whether the timing-hypothesis window the literature actually describes still applies to a start this late.

A BRCA1 carrier with no personal cancer history has just had her ovaries removed to reduce cancer risk — and now faces a genuine, unresolved tension over whether replacing the estrogen that surgery just eliminated reopens the door it was built to close.

A PCOS patient trying to conceive is offered an off-label aromatase inhibitor with better trial numbers over the decades-old, FDA-labeled standard — a case about weighing real evidence against a regulatory default.

A competitive athlete's amenorrhea is genuinely reversible — and genuinely unpredictable in how long that reversal takes, against a fertility window she says she doesn't have to spare.

Continuous sertraline helped, partially, at a side-effect cost real enough to nearly end the trial — a case about reading a partial response correctly rather than simply calling it a failure and switching drug classes.

Hormonal suppression is genuinely controlling her endometriosis pain — and genuinely working against the fertility timeline she's set for next year, since the same mechanism does both.

Her anemia is severe enough that a medical bridge and definitive surgery aren't really competing options — the real question is which drug, and for how long, before the operating room.

A migraine-with-aura history and a prior VTE both rule out estrogen outright — but whether progestin-only methods carry meaningful residual risk of their own, or none the guidelines actually recognize, is a genuinely closer question than the safety conversation usually treats it as.

A time-sensitive contraceptive failure meets a genuinely contested efficacy question — whether levonorgestrel still works as well at her weight, and what to actually tell her about it in the next few hours.

The one androgen indication in women with real randomized evidence behind it — and no FDA-approved product in the U.S. to actually prescribe for it.

Two well-designed randomized trials reached genuinely different bottom lines on the same drug — and which one actually describes this patient is a matter of matching her specific presentation, not picking a favorite.

Her vaginal symptoms are severe enough to justify real intervention — on a drug whose entire job is keeping her estrogen as low as possible, which makes even a low-dose local option a genuinely contested choice.

A routine hormone-replacement visit is complicated by a mildly dilated aorta — a real, structural finding in a condition where estrogen didn't cause the risk but a route choice might still modify it.

The standard pubertal-induction protocol is slow by design — and she has already waited six years longer than her peers, which makes the case for going slower still a genuinely harder sell than it would be for a 13-year-old just starting.

Her preferred method is genuinely, mechanistically undermined by the drug she's about to start for a completely unrelated reason — a real interaction, not a guideline being cautious for its own sake.